Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Response to: Patient-centred medical education: A proposed definition

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Birgitte Klug Albertsen
  • Arja Harila-Saari
  • Kirsi Jahnukainen
  • Päivi Lähteenmäki
  • Pekka Riikonen
  • Merja Möttönen
  • Birgitte Lausen
View graph of relations

Acute lymphoblastic leukemia (ALL) is a rare disease in infants. Asparaginase is an essential part of the treatment, and there Acute is a need to evaluate the efficiency and safety of this drug in this age group. We evaluated the pharmacokinetics of intramuscularly administered native E. coli asparaginase (Asparaginase Medac®) and PEG-asparaginase (Oncaspar®) as well as hypersensitivity reactions during treatment in Interfant-06 ( : NCT01025804). All patients without hypersensitivity had sufficiently high enzyme activity levels during treatment with both preparations. Patients with hypersensitivity reactions during treatment, characterized by the presence of either or not of clinical symptoms and no measurable enzyme activity, received ineffective therapy. For optimization of the bad prognosis in infant ALL, therapeutic drug monitoring should be performed for identification of patients who should be switched to a different asparaginase preparation because of inactivation of the drug.

Original languageEnglish
JournalLeukemia and Lymphoma
Issue number6
Pages (from-to)1469-1475
Number of pages7
Publication statusPublished - 2019

ID: 59087987